Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 4/20 | 0.72 |
| ▸ | EGFR | P00533 | 17/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967305 | 1.00 | FBP1 (0.72) | FBP1EGFRERBB2KDM4EGAK | |
| SCHEMBL4968920 | 1.00 | FBP1 (0.72) | FBP1EGFRERBB2KDM4EGAK | |
| SCHEMBL1417695 | 0.97 | FBP1 (0.75) | FBP1EGFRERBB2KDM4EGAK | |
| SCHEMBL1418026 | 0.93 | FBP1 (0.74) | FBP1EGFRERBB2KDM4EGAK | |
| SCHEMBL1418085 | 0.93 | FBP1 (0.74) | FBP1EGFRERBB2KDM4EGAK | |
| SCHEMBL5147122 | 0.91 | FBP1 (0.65) | FBP1EGFRERBB2ERBB4 | |
| SCHEMBL4967582 | 0.90 | FBP1 (0.57) | FBP1EGFRERBB2KDRABCG2 | |
| SCHEMBL5115813 | 0.90 | FBP1 (0.57) | FBP1EGFRERBB2KDRABCG2 | |
| SCHEMBL5123093 | 0.90 | FBP1 (0.57) | FBP1EGFRERBB2KDRABCG2 | |
| SCHEMBL13699309 | 0.90 | FBP1 (0.67) | FBP1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461166-B2 | Anilinoquinazolinyl amide derivatives; radiolabels as bioprobes for Positron Emission Tomography and Single Photon Emission Computed Tomography, and as radiopharmaceuticals for radiotherapy; improved solubility, bioavailability, biostability | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2013-06-11 | — | — | US | disclosed |
| EP-1957468-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4 - (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | T.K. Signal Ltd. (IL) | 2008-08-20 | — | — | EP | disclosed |
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | T.K. SIGNAL LTD. (IL) | 2008-03-06 | — | — | US | disclosed |
| WO-2007029251-A2 | POLYALKYLENE GLYCOL DERIVATIVES OF 4- (PHENYLAMINO)QUINAZOLINES USEFUL AS IRREVERSIBLE INHIBITORS OF EPIDERMAL GR0WTH FACT0R RECEPTOR TYROSINE KINASE | T.K. SIGNAL LTD. (IL) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080056990-A1 | Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase | EGFR, TK1, ERBB2 | FBP1 1341/4885EGFR 1/4885ERBB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.